Recently, PRMT5, the major type II protein arginine methyltransferase, has also been reported as a suppressor of anti-tumor immunity in melanoma in a cGAS-independent manner through methylating IFI16 (a parallel signaling of cGAS/STING) and NLRC5 to block the transcription of type I interferons and major histocompatibility complex class I (MHC-I)30–32. This evidence concerns the gene NLRC5 and neoplasm.